Trial · NCT03175367
Participant flow42
How many started, completed or left each group, period by period.
1 to 20 of 42
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Double-blind Treatment Period (DBTP) | STARTED | Group A: Placebo SC QW (DBTP) | 39 | |
| Double-blind Treatment Period (DBTP) | STARTED | Group A: Evinacumab 300 mg SC Q2W (DBTP) | 39 | |
| Double-blind Treatment Period (DBTP) | STARTED | Group A: Evinacumab 300 mg SC QW (DBTP) | 42 | |
| Double-blind Treatment Period (DBTP) | STARTED | Group A: Evinacumab 450 mg SC QW (DBTP) | 40 | |
| Double-blind Treatment Period (DBTP) | STARTED | Group B: Placebo IV Q4W (DBTP to OLTP) | 33 | |
| Double-blind Treatment Period (DBTP) | STARTED | Group B: Evinacumab 5 mg/kg IV Q4W (DBTP to OLTP) | 35 | |
| Double-blind Treatment Period (DBTP) | STARTED | Group B: Evinacumab 15 mg/kg IV Q4W (DBTP to OLTP) | 38 | |
| Double-blind Treatment Period (DBTP) | COMPLETED | Group A: Placebo SC QW (DBTP) | 30 | |
| Double-blind Treatment Period (DBTP) | COMPLETED | Group A: Evinacumab 300 mg SC Q2W (DBTP) | 31 | |
| Double-blind Treatment Period (DBTP) | COMPLETED | Group A: Evinacumab 300 mg SC QW (DBTP) | 30 | |
| Double-blind Treatment Period (DBTP) | COMPLETED | Group A: Evinacumab 450 mg SC QW (DBTP) | 30 | |
| Double-blind Treatment Period (DBTP) | COMPLETED | Group B: Placebo IV Q4W (DBTP to OLTP) | 31 | |
| Double-blind Treatment Period (DBTP) | COMPLETED | Group B: Evinacumab 5 mg/kg IV Q4W (DBTP to OLTP) | 32 | |
| Double-blind Treatment Period (DBTP) | COMPLETED | Group B: Evinacumab 15 mg/kg IV Q4W (DBTP to OLTP) | 34 | |
| Double-blind Treatment Period (DBTP) | NOT COMPLETED | Group A: Placebo SC QW (DBTP) | 9 | |
| Double-blind Treatment Period (DBTP) | NOT COMPLETED | Group A: Evinacumab 300 mg SC Q2W (DBTP) | 8 | |
| Double-blind Treatment Period (DBTP) | NOT COMPLETED | Group A: Evinacumab 300 mg SC QW (DBTP) | 12 | |
| Double-blind Treatment Period (DBTP) | NOT COMPLETED | Group A: Evinacumab 450 mg SC QW (DBTP) | 10 | |
| Double-blind Treatment Period (DBTP) | NOT COMPLETED | Group B: Placebo IV Q4W (DBTP to OLTP) | 2 | |
| Double-blind Treatment Period (DBTP) | NOT COMPLETED | Group B: Evinacumab 5 mg/kg IV Q4W (DBTP to OLTP) | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03175367/flow